OBJECTIVE: Cardiovascular disease (CVD) is the leading cause of death in patients with serious mental illness (SMI) and in patients with Type 2 diabetes. Inadequate pharmacologic care for CVD may partially explain poor health outcomes in individuals with both conditions. We sought to identify patients in this group at greatest risk for suboptimal pharmacologic management. METHODS: Among individuals with Type 2 diabetes and SMI identified from Maryland Medicaid data, we evaluated patient and service utilization factors associated with the prescription of HMG-CoA reductase inhibitors ("statins") for hyperlipidemia and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for chronic kidney disease, congestive heart failure, and hypertension. RESULTS: From 2001 to 2003, the annual prevalence of use of statins and ACE-inhibitors/ARBs ranged from 44 to 59%, with rates increasing each year. Being female, having certain cardiovascular conditions, and having a greater number of outpatient visits for diabetes increased the odds of receiving statins and ACE-inhibitors/ARBs. More frequent contact with the mental health system was associated with a lower likelihood of receipt of both medication classes; having a substance use disorder was associated with reduced use of statins. African-Americans were less likely than Caucasians to receive statins, but more likely to receive prescriptions for ACE-inhibitors/ARBs. CONCLUSIONS: Although the use of cardioprotective medications in individuals with Type 2 diabetes and SMI increased over the study period, a considerable proportion of patients remained inadequately managed despite their considerable cardiac risk. Further study should focus on observed racial variations and strategies to increase the capacity of mental health contacts to improve prescribing of these agents.
OBJECTIVE:Cardiovascular disease (CVD) is the leading cause of death in patients with serious mental illness (SMI) and in patients with Type 2 diabetes. Inadequate pharmacologic care for CVD may partially explain poor health outcomes in individuals with both conditions. We sought to identify patients in this group at greatest risk for suboptimal pharmacologic management. METHODS: Among individuals with Type 2 diabetes and SMI identified from Maryland Medicaid data, we evaluated patient and service utilization factors associated with the prescription of HMG-CoA reductase inhibitors ("statins") for hyperlipidemia and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for chronic kidney disease, congestive heart failure, and hypertension. RESULTS: From 2001 to 2003, the annual prevalence of use of statins and ACE-inhibitors/ARBs ranged from 44 to 59%, with rates increasing each year. Being female, having certain cardiovascular conditions, and having a greater number of outpatient visits for diabetes increased the odds of receiving statins and ACE-inhibitors/ARBs. More frequent contact with the mental health system was associated with a lower likelihood of receipt of both medication classes; having a substance use disorder was associated with reduced use of statins. African-Americans were less likely than Caucasians to receive statins, but more likely to receive prescriptions for ACE-inhibitors/ARBs. CONCLUSIONS: Although the use of cardioprotective medications in individuals with Type 2 diabetes and SMI increased over the study period, a considerable proportion of patients remained inadequately managed despite their considerable cardiac risk. Further study should focus on observed racial variations and strategies to increase the capacity of mental health contacts to improve prescribing of these agents.
Authors: Janice G Douglas; George L Bakris; Murray Epstein; Keith C Ferdinand; Carlos Ferrario; John M Flack; Kenneth A Jamerson; Wendell E Jones; Julian Haywood; Randall Maxey; Elizabeth O Ofili; Elijah Saunders; Ernesto L Schiffrin; Domenic A Sica; James R Sowers; Donald G Vidt Journal: Arch Intern Med Date: 2003-03-10
Authors: Lisa B Dixon; David A Adler; Jeffrey L Berlant; Rebecca A Dulit; Beth Goldman; Ann L Hackman; David W Oslin; Samuel G Siris; William A Sonis; Marcia Valenstein Journal: Psychiatr Serv Date: 2007-05 Impact factor: 3.084
Authors: Richard W Goldberg; Julie A Kreyenbuhl; Deborah R Medoff; Faith B Dickerson; Karen Wohlheiter; Li Juan Fang; Clayton H Brown; Lisa B Dixon Journal: Psychiatr Serv Date: 2007-04 Impact factor: 3.084
Authors: Benjamin G Druss; Liping Zhao; Janet R Cummings; Ruth S Shim; George S Rust; Steven C Marcus Journal: Med Care Date: 2012-05 Impact factor: 2.983
Authors: Leonard E Egede; Mulugeta Gebregziabher; Yumin Zhao; Clara E Dismuke; Rebekah J Walker; Kelly J Hunt; R Neal Axon Journal: PLoS One Date: 2014-08-01 Impact factor: 3.240
Authors: Masao Iwagami; Kathryn E Mansfield; Joseph F Hayes; Kate Walters; David Pj Osborn; Liam Smeeth; Dorothea Nitsch; Laurie A Tomlinson Journal: Clin Epidemiol Date: 2018-04-16 Impact factor: 4.790